BACKGROUND: Large B-cell lymphoma (LBCL) with interferon regulatory factor 4 (IRF4) rearrangement (LBCL-IRF4) is a rare subtype of LBCL, with a high prevalence in Waldeyer's ring as well as the neck, head and gastrointestinal lymph nodes.
MATERIALS AND METHODS: A patient with 2-month clinical symptoms of nasal obstruction and facial swelling was reported in this short review. A nasal endoscopy examination revealed a neoplasm in the inferior nasal meatus. Both CT and enhanced MRI showed that a soft tissue occupied the nasolacrimal duct, with bone destruction, and extended into the left nasal cavity and left lacrimal gland area. Then, a biopsy of the neoplasm in the inferior nasal meatus was performed.
RESULTS: HE staining results showed that neoplastic cells presented diffuse growth patterns, abundant cytoplasm, vacuole shape, lightly stained nuclei, and irregular nuclear membrane. Immunohistochemistry staining results revealed MUM1(+), Bcl- 6(+), CD20(+), CD79α(+), and CD10(+). FISH analyses detected positive IRF4 rearrangement. LBCL-IRF4 was diagnosed in the patient. The patient received treatment with four cycles of R-CHOP and two times of rituximab, followed up for 2 years, and finally got complete remission.
CONCLUSION: For the first time, we summarize the imaging and pathological features, drug treatment, and curative effect of LBCL-IRF4 in the nasolacrimal duct.
Salaverria I.; Philipp C.; Oschlies I.; Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011,118(1),139-147
[DOI:
10.1182/blood-2011-01-330795]
Grimm K.E.; O’Malley D.P.; Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol 2019,38,6-10
[DOI:
10.1016/j.anndiagpath.2018.09.014]
Quintanilla-Martinez L.; Laurent C.; Soma L.; Emerging entities: High-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop. Virchows Arch 2023,483(3),281-298
[DOI:
10.1007/s00428-023-03590-x]
Streich S.; Frauenfeld L.; Otto F.; Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer’s ring in adults. Virchows Arch 2023,482(3),551-560
[DOI:
10.1007/s00428-023-03516-7]
Tamura A.; Miura I.; Iida S.; Interphase detection of immunoglobulin heavy chain gene translocations with specific oncogene loci in 173 patients with B-cell lymphoma. Cancer Genet Cytogenet 2001,129(1),1-9
[DOI:
10.1016/S0165-4608(01)00436-8]
Lin L.; Gerth A.J.; Peng S.L.; Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J Exp Med 2004,200(1),115-122
[DOI:
10.1084/jem.20040612]
Xu W.D.; Pan H.F.; Ye D.Q.; Xu Y.; Targeting IRF4 in autoimmune diseases. Autoimmun Rev 2012,11(12),918-924
[DOI:
10.1016/j.autrev.2012.08.011]
Falini B.; Fizzotti M.; Pucciarini A.; A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000,95(6),2084-2092
[DOI:
10.1182/blood.V95.6.2084]
Ramis-Zaldivar J.E.; Gonzalez-Farré B.; Balagué O.; Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood 2020,135(4),274-286
[DOI:
10.1182/blood.2019002699]
Yang Y.; Shaffer A.L.; Emre N.C.T.; Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012,21(6),723-737
[DOI:
10.1016/j.ccr.2012.05.024]
Chen W.; Gong Q.X.; Li X.; Clinicopathological study of large B-cell lymphoma with IRF4 rearrangement. Zhonghua Bing Li Xue Za Zhi 2020,49(10),1003-1008
[PMID:
32992413]
Liu Q.; Salaverria I.; Pittaluga S.; Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013,37(3),333-343
[DOI:
10.1097/PAS.0b013e31826b9b57]
Wenzinger C.; Williams E.; Gru A.A.; Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the who classification of tumors of hematopoietic and lymphoid tissues. Curr Hematol Malig Rep 2018,13(4),275-278
Zhou L.; Gu B.; Shen X.; Binshen O.; Dong L.; Zhou J.; B cell lymphoma with IRF4 rearrangement: A clinicopathological study of 13 cases. Pathol Int 2021,71(3),183-190
[DOI:
10.1111/pin.13067]
Iqbal J.; Shen Y.; Huang X.; Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood 2015,125(7),1137-1145
[DOI:
10.1182/blood-2014-04-566778]
Granai M.; Lazzi S.; Early pattern of large B-cell lymphoma with IRF4 rearrangement. Blood 2020,136(6),769
[DOI:
10.1182/blood.2020006406]
Humans
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Gene Rearrangement
Interferon Regulatory Factors
Lymphoma, Large B-Cell, Diffuse
Nasolacrimal Duct
Rituximab
Vincristine
